On March 23, Chimin Health Management Co.Ltd(603222) disclosed the annual report of 2021. During the reporting period, the company achieved a revenue of 1.098 billion yuan, an increase of 25.16% year-on-year; The net profit attributable to the parent company was 148 million yuan, a year-on-year increase of 220602%; The non net profit deducted was 111 million yuan, a year-on-year increase of 393.08%.
Chimin Health Management Co.Ltd(603222) said that the company’s net profit attributable to the parent company and net profit deducted from the parent company increased significantly compared with the same period of the previous year, mainly due to the significant increase in the sales of safety syringes (needles) of the company. During the reporting period, Jumin biosafety syringes (needles), a wholly-owned subsidiary of the company, achieved annual sales of about 600 million, an increase of 138.94% over the same period of last year; The net profit was 152 million yuan, an increase of 193.33% over the same period last year.
In the medical device sector, the company achieved an operating revenue of 591 million yuan in 2021, with a year-on-year increase of 52.21%; The gross profit margin was 50.13%, an increase of 8.56 percentage points over the previous year. The company said that the revenue and gross profit margin of the medical device sector increased significantly compared with the same period of the previous year, mainly due to the increase in the sales of safety syringes (needles) for export products and the increase in the proportion of sales. During the reporting period, in order to meet the market demand, Jumin biology, a wholly-owned subsidiary of the company, invested in the construction of four safety syringe (needle) production lines. By September 2021, after all the four new production lines were put into operation, the company’s safety syringe (needle) production capacity was increased to 850 million pieces / year. It is reported that Jumin biology is a OEM manufacturer of safety syringes, safety injection needles and other products of RTI company in the United States. The two sides have cooperated for more than ten years. After signing the authorization license for the production and sale of safety syringes in China with American RTI company in 2018, Jumin biological started the application for registration in China, obtained the medical device registration certificate issued by the State Drug Administration in April and July 2021 respectively, and the safety syringe (needle) products were allowed to enter the Chinese market.
In the medical service sector, the company achieved a revenue of 244 million yuan in 2021, a year-on-year increase of 10.5%; The gross profit margin was 42.53%, an increase of 9.66 percentage points over the previous year. The company said that the increase in medical service income was mainly driven by the increase in income of Boao International Hospital, a holding subsidiary. Boao International Hospital of Shanghai University of traditional Chinese medicine under the company has a total land area of about 81.2 mu, a total construction area of 65000 square meters and an approved number of 560 beds. The hospital consists of international regenerative medicine research center, high-end medical beauty center, neurological disease precision treatment center, bone and joint disease prevention center and other departments. It has the only international regenerative medicine laboratory in China that has passed the GMP certification of the Ministry of health and welfare of Japan. It has built four core technology platforms, including cell storage, international standard cell preparation, clinical research of cell therapy, and technology transformation of stem cells and regenerative medicine.
In addition, the new hospital project of Ezhou No.2 Hospital is an investment project invested by the company through non-public offering of shares in April 2021. The project is located in Binhu West Road, Ezhou City, Hubei Province, covering an area of about 65 mu, with a total construction area of 113300 square meters, 1000 planned beds and a total investment of nearly 600 million yuan. The company said that during the reporting period, with the funds raised in place, the construction of the project was rapidly promoted, but affected by the epidemic, the project progress was delayed and the goal of opening by the end of 2021 was not achieved. Up to now, the internal decoration, supporting facilities construction and equipment commissioning of the project are accelerating. The company strives to open the new hospital of Ezhou No. 2 hospital as soon as possible and contribute new performance growth points to the company.
